FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4287485342> ?p ?o ?g. }

• W4287485342 endingPage "12587" @default.
• W4287485342 startingPage "12575" @default.
• W4287485342 abstract "Favipiravir has demonstrated efficacy against the SARS-CoV-2 virus in several preliminary studies. This study aimed to evaluate the efficacy and safety of favipiravir for treatment of mild to moderate COVID-19 in outpatients and hospitalized patients. We conducted an open-label, randomized, active-controlled trial of a generic form of favipiravir in patients with COVID-19 confirmed by PCR-test. Eligible patients (18-60 years) after stratification were randomly assigned (in a 2:1 ratio) to receive either favipiravir (1800 mg BID on day 1, followed by 800 mg BID for up to 9 days), or standard of care (SOC) treatment (umifenovir + intranasal interferon alpha-2b, or hydroxychloroquine) for up to 10 days. The co-primary outcomes were the time to clinical improvement and the time to viral clearance. Among 190 patients assessed for eligibility 168 were randomized to favipiravir (n=112) or to SOC (n=56) group. The median time to clinical improvement was 6.0 days (IQR 4.0; 9.3) in the favipiravir group and 10.0 (IQR 5.0; 21.0) days in the SOC group; the median difference was 4 days (HR 1.63; 95% CI 1.14-2.34; P=0.007). The statistically significant difference in the median time to viral clearance was observed only for hospitalized patients: 3.0 (IQR 3.0; 3.0) days in the favipiravir group vs. 5.0 (IQR 4.5; 5.5) days in the SOC group (HR 2.11; 95% CI 1.04-4.31; P=0.038). The rate of viral elimination on Day 5 in the favipiravir group was significantly higher than in SOC group: 81.2% vs. 67.9% (RR 1.22; 05% CI 1.00-1.48; P=0.022). The rate of clinical improvement on Day 7 in the favipiravir group was 1.5-fold higher than in SOC group: 52.7% vs. 35.8% (RR 1.50; 95% CI 1.02-2.22; P=0.020). Favipiravir was well-tolerated and the most common adverse reactions were asymptomatic hyperuricemia, transient elevation of ALT & AST, and mild gastrointestinal disorders. Favipiravir was superior to the SOC in shortening the time to clinical improvement in patients with mild to moderate COVID-19." @default.
• W4287485342 created "2022-07-25" @default.
• W4287485342 creator A5000648764 @default.
• W4287485342 creator A5004895643 @default.
• W4287485342 creator A5007180180 @default.
• W4287485342 creator A5009283910 @default.
• W4287485342 creator A5025925197 @default.
• W4287485342 creator A5027090196 @default.
• W4287485342 creator A5034480348 @default.
• W4287485342 creator A5041760675 @default.
• W4287485342 creator A5044576325 @default.
• W4287485342 creator A5050789532 @default.
• W4287485342 creator A5056120026 @default.
• W4287485342 creator A5070559057 @default.
• W4287485342 creator A5081325549 @default.
• W4287485342 creator A5082142541 @default.
• W4287485342 date "2021-01-01" @default.
• W4287485342 modified "2023-10-16" @default.
• W4287485342 title "Phase 3 trial of coronavir (favipiravir) in patients with mild to moderate COVID-19." @default.
• W4287485342 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34956474" @default.
• W4287485342 hasPublicationYear "2021" @default.
• W4287485342 type Work @default.
• W4287485342 citedByCount "12" @default.
• W4287485342 countsByYear W42874853422022 @default.
• W4287485342 countsByYear W42874853422023 @default.
• W4287485342 crossrefType "journal-article" @default.
• W4287485342 hasAuthorship W4287485342A5000648764 @default.
• W4287485342 hasAuthorship W4287485342A5004895643 @default.
• W4287485342 hasAuthorship W4287485342A5007180180 @default.
• W4287485342 hasAuthorship W4287485342A5009283910 @default.
• W4287485342 hasAuthorship W4287485342A5025925197 @default.
• W4287485342 hasAuthorship W4287485342A5027090196 @default.
• W4287485342 hasAuthorship W4287485342A5034480348 @default.
• W4287485342 hasAuthorship W4287485342A5041760675 @default.
• W4287485342 hasAuthorship W4287485342A5044576325 @default.
• W4287485342 hasAuthorship W4287485342A5050789532 @default.
• W4287485342 hasAuthorship W4287485342A5056120026 @default.
• W4287485342 hasAuthorship W4287485342A5070559057 @default.
• W4287485342 hasAuthorship W4287485342A5081325549 @default.
• W4287485342 hasAuthorship W4287485342A5082142541 @default.
• W4287485342 hasConcept C126322002 @default.
• W4287485342 hasConcept C168563851 @default.
• W4287485342 hasConcept C197934379 @default.
• W4287485342 hasConcept C2779134260 @default.
• W4287485342 hasConcept C2779772310 @default.
• W4287485342 hasConcept C3008058167 @default.
• W4287485342 hasConcept C524204448 @default.
• W4287485342 hasConcept C535046627 @default.
• W4287485342 hasConcept C71924100 @default.
• W4287485342 hasConceptScore W4287485342C126322002 @default.
• W4287485342 hasConceptScore W4287485342C168563851 @default.
• W4287485342 hasConceptScore W4287485342C197934379 @default.
• W4287485342 hasConceptScore W4287485342C2779134260 @default.
• W4287485342 hasConceptScore W4287485342C2779772310 @default.
• W4287485342 hasConceptScore W4287485342C3008058167 @default.
• W4287485342 hasConceptScore W4287485342C524204448 @default.
• W4287485342 hasConceptScore W4287485342C535046627 @default.
• W4287485342 hasConceptScore W4287485342C71924100 @default.
• W4287485342 hasIssue "11" @default.
• W4287485342 hasLocation W42874853421 @default.
• W4287485342 hasOpenAccess W4287485342 @default.
• W4287485342 hasPrimaryLocation W42874853421 @default.
• W4287485342 hasRelatedWork W11437557 @default.
• W4287485342 hasRelatedWork W12959130 @default.
• W4287485342 hasRelatedWork W17026572 @default.
• W4287485342 hasRelatedWork W17659181 @default.
• W4287485342 hasRelatedWork W17747543 @default.
• W4287485342 hasRelatedWork W18264973 @default.
• W4287485342 hasRelatedWork W20224748 @default.
• W4287485342 hasRelatedWork W2507035 @default.
• W4287485342 hasRelatedWork W5667359 @default.
• W4287485342 hasRelatedWork W6918129 @default.
• W4287485342 hasVolume "13" @default.
• W4287485342 isParatext "false" @default.
• W4287485342 isRetracted "false" @default.
• W4287485342 workType "article" @default.